Analyst firms · UBS · ALKS
UBS ALKS price target and rating history
Alkermes plc (ALKS) · Health Care
UBS rates Alkermes plc (ALKS) Buy with a $42 price target, as of its latest action on Jun 17, 2025. It has published 4 rating actions on ALKS since October 2023, including 2 upgrades and 1 downgrade. Across 3 firms with a ALKS price target in the last 12 months, the median target is $45.
- Current rating
- Buy
- Price target
- $42
- Median target, all firms
- $45
- Actions on ALKS
- 4
UBS price target on ALKS
Every UBS rating on ALKS
- Jun 17, 2025
- Mar 4, 2025
- Feb 20, 2024
- Oct 17, 2023
How other firms rate ALKS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Buy | $55 | Oct 16, 2026 |
| BofA Securities | Underperform | $38 | Jun 29, 2026 |
| Wolfe Research | Outperform | $45 | Feb 24, 2026 |
Questions about UBS and ALKS
- What is UBS's price target for ALKS?
- UBS's latest stated price target for Alkermes plc (ALKS) is $42, from its action on Jun 17, 2025.
- What is UBS's rating on ALKS?
- UBS rates ALKS Buy, a bullish rating, as of Jun 17, 2025.
- When did UBS last change its view on ALKS?
- On Jun 17, 2025, UBS upgrades to Buy from Neutral, price target $42.
- How does UBS's ALKS target compare with other analysts?
- Across 3 firms with a ALKS price target in the last 12 months, the median target is $45.
More ALKS rating histories
All UBS ratingsALKS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.